These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 14629823

  • 1. A novel monoclonal antibody design for radioimmunotherapy.
    Forero A, Meredith RF, Khazaeli MB, Carpenter DM, Shen S, Thornton J, Schlom J, LoBuglio AF.
    Cancer Biother Radiopharm; 2003 Oct; 18(5):751-9. PubMed ID: 14629823
    [Abstract] [Full Text] [Related]

  • 2. A CDR-grafted (humanized) domain-deleted antitumor antibody.
    Slavin-Chiorini DC, Kashmiri SV, Lee HS, Milenic DE, Poole DJ, Bernon E, Schlom J, Hand PH.
    Cancer Biother Radiopharm; 1997 Oct; 12(5):305-16. PubMed ID: 10851481
    [Abstract] [Full Text] [Related]

  • 3. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY, Chu DZ, Yamauchi D, Odom-Maryon TL, Williams LE, Liu A, Esteban JM, Wu AM, Primus FJ, Beatty JD, Shively JE, Raubitschek AA.
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [Abstract] [Full Text] [Related]

  • 4. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [Abstract] [Full Text] [Related]

  • 5. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ, Rogers BE, Khazaeli MB, Mayo MS, Milenic DE, Kashmiri SV, Anderson CJ, Chappell LL, Brechbiel MW, Curiel DT.
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [Abstract] [Full Text] [Related]

  • 6. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
    Storto G, Buchegger F, Waibel R, Kuenzi G, Offord RE, Schubiger PA, Gillet M, Delaloye AB.
    Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
    [Abstract] [Full Text] [Related]

  • 7. Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma.
    Divgi CR, Scott AM, Gulec S, Broussard EK, Levy N, Young C, Capitelli P, Daghighian F, Williams JM, Finn RD.
    Clin Cancer Res; 1995 Dec; 1(12):1503-10. PubMed ID: 9815950
    [Abstract] [Full Text] [Related]

  • 8. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
    Rogers BE, Roberson PL, Shen S, Khazaeli MB, Carpenter M, Yokoyama S, Brechbiel MW, LoBuglio AF, Buchsbaum DJ.
    Cancer Biother Radiopharm; 2005 Oct; 20(5):502-13. PubMed ID: 16248766
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies.
    Sharkey RM, Juweid M, Shevitz J, Behr T, Dunn R, Swayne LC, Wong GY, Blumenthal RD, Griffiths GL, Siegel JA.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5935s-5945s. PubMed ID: 7493374
    [Abstract] [Full Text] [Related]

  • 10. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
    Behr TM, Sharkey RM, Juweid MI, Dunn RM, Ying Z, Zhang CH, Siegel JA, Gold DV, Goldenberg DM.
    Cancer Res; 1996 Apr 15; 56(8):1805-16. PubMed ID: 8620497
    [Abstract] [Full Text] [Related]

  • 11. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
    Divgi CR, Scott AM, Dantis L, Capitelli P, Siler K, Hilton S, Finn RD, Kemeny N, Kelsen D, Kostakoglu L.
    J Nucl Med; 1995 Apr 15; 36(4):586-92. PubMed ID: 7699446
    [Abstract] [Full Text] [Related]

  • 12. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ.
    Clin Cancer Res; 1999 May 15; 5(5):953-61. PubMed ID: 10353726
    [Abstract] [Full Text] [Related]

  • 13. Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.
    Shen S, Forero A, Meredith RF, LoBuglio AF.
    Cancer Biother Radiopharm; 2011 Feb 15; 26(1):127-33. PubMed ID: 21355784
    [Abstract] [Full Text] [Related]

  • 14. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
    Macey DJ, Grant EJ, Kasi L, Rosenblum MG, Zhang HZ, Katz RL, Rieger PT, LeBherz D, South M, Greiner JW, Schlom J, Podoloff DA, Murray JL.
    Clin Cancer Res; 1997 Sep 15; 3(9):1547-55. PubMed ID: 9815842
    [Abstract] [Full Text] [Related]

  • 15. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
    Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, Germain JS, Richards EC, Larson SM, Oettgen HF.
    J Clin Oncol; 1994 Aug 15; 12(8):1561-71. PubMed ID: 8040668
    [Abstract] [Full Text] [Related]

  • 16. Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer.
    Hajjar G, Sharkey RM, Burton J, Zhang CH, Yeldell D, Matthies A, Alavi A, Losman MJ, Brenner A, Goldenberg DM.
    Clin Colorectal Cancer; 2002 May 15; 2(1):31-42. PubMed ID: 12453334
    [Abstract] [Full Text] [Related]

  • 17. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer.
    Kramer EL, Liebes L, Wasserheit C, Noz ME, Blank EW, Zabalegui A, Melamed J, Furmanski P, Peterson JA, Ceriani RL.
    Clin Cancer Res; 1998 Jul 15; 4(7):1679-88. PubMed ID: 9676842
    [Abstract] [Full Text] [Related]

  • 18. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
    Mittal BB, Zimmer MA, Sathiaseelan V, Benson AB, Mittal RR, Dutta S, Rosen ST, Spies SM, Mettler JM, Groch MW.
    Cancer; 1996 Nov 01; 78(9):1861-70. PubMed ID: 8909304
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients.
    Xiao J, Horst S, Hinkle G, Cao X, Kocak E, Fang J, Young D, Khazaeli M, Agnese D, Sun D, Martin E.
    Cancer Biother Radiopharm; 2005 Feb 01; 20(1):16-26. PubMed ID: 15778575
    [Abstract] [Full Text] [Related]

  • 20. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.
    Kashmiri SV, Shu L, Padlan EA, Milenic DE, Schlom J, Hand PH.
    Hybridoma; 1995 Oct 01; 14(5):461-73. PubMed ID: 8575795
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.